Erythromycin Suppresses the Expression of Cyclooxygenase-2 in Rheumatoid Synovial Cells

Journal of Rheumatology

Volumn 31, Issue 3, 2004, Pages 436-441

  Fumimori, Takehide ^a   Honda, Seiyo ^a   Migita, Kiyoshi ^b   Hamada, Minako ^a   Yoshimuta, Taro ^a   Honda, Junichi ^a   Fukuda, Takaaki ^a   Suzuki, Ritsu ^c   Gotoh, Masafumi ^c   Eguchi, Katsumi ^a   Aizawa, Hisamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KURUME UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Cyclooxygenase 2 interleukin 1 ; Erythromycin; p38 mitogen activated protein kinase; Synovial cells

Indexed keywords

CYCLOOXYGENASE 2; ERYTHROMYCIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DRUG ACTIVITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYCLOOXYGENASE 2; ERYTHROMYCIN; HUMANS; INTERLEUKIN-1; ISOENZYMES; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN SYNTHESIS INHIBITORS; SYNOVIAL MEMBRANE;

EID: 12144289353     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Zvaifler NJ, Firestein GS. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
2. 2 in prostaglandin biosynthesis. Biochem Pharmacol 1976;25:285-91.
3. 2 in human synovial cells. Arthritis Rheum 1988;31:126-30.
4. Robinson DR, Tashjian AH Jr, Levine L. Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 1975;56:1181-8.
5. Dayer JM, Krane SM, Russell RG, Robinson DR. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci USA 1976;73:945-9.
6. Dayer JM, Robinson DR, Krane SM. Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear Cells. J Exp Med 1977;145:1399-404.
7. 2. J Immunol 1995;155:3570-7.
8. Sano H, Hla T, Maier JA, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
9. Mikasa K, Kita E, Sawaki M, et al. The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice. J Antimicrob Chemother 1992;30:339-48.
10. Agen C, Danesi R, Blandizzi C, et al. Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role. Agents Actions 1993;38:85-90.
11. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 1989;15:527-33.
12. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1990;34:863-70.
13. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994;105:308-16.
14. Kawashima Y, Kameo K, Kato M, et al. Structure-activity studies of 3-benzoylpropionic acid derivatives suppressing adjuvant arthritis. Chem Pharm Bull (Tokyo) 1992;40:774-7.
15. Honda S, Migita K, Hirai Y, et al. Induction of COX-2 expression by nitric oxide in rheumatoid synovial cells. Biochem Biophys Res Commun 2000;268:928-31.
16. Renard P, Emest I, Houbion A, et al. Development of a sensitive multi-well colorimetric assay for active NF kappa B. Nucl Acids Res 2001;29:E21. Website: www.nar.oupjournals.org [cited December 19, 2003].
17. Nakao S, Ogata Y, Shimizu-Sasaki E, Yamazaki M, Furuyama S, Sugiya H. Activation of NF kappa B is necessary for IL-1 beta-induced cyclooxygenase-2 (COX-2) expression in human gingival fibroblasts. Mol Cell Biochem 2000;209:113-8.
18. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-8.
19. Geng Y, Blanco FJ, Cornelisson M, Lotz M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J. Immunol 1995;155:796-801.
20. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1 994;93:1095-101.
21. Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996;35:711-8.
22. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63.
23. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 1997;40:226-36.
24. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-kappa B, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 1999;43:2678-84.
25. Laporte JD, Moore PE, Abraham JH, et al. Role of ERK MAP kinases in responses of cultured human airway smooth muscle cells to IL-1 beta. Am J Physiol 1999;277:L943-51.
26. Carter AB, Hunninghake GW. A constitutive active MEK-ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. J Biol Chem 2000;275:27858-64.
27. Guan Z, Buckman SY, Miller BW, Springer LD, Morrison AR. Interleukin-1 beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem 1998;273:28670-6.
28. Dean JL, Brook M, Clark AR, Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999;274:264-9.
29. Faour WH, He Y, He QW, et al. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 2001;276:31720-31.
30. Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett 1998;439:75-80.
31. Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogen-activated protein kinase is required for NF-kappa B-dependent gene expression. The role of TATA-binding protein. J Biol Chem 1999;274:30858-63.
32. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 2000;20:4265-74.
33. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 2001;21:771-80.
34. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
35. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997;26 Suppl 1:2-10.
36. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-9.
37. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991;58:145-9.
38. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157:1829-32.
39. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994;106:1116-23.
40. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997;156:266-71.